{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T11:58:50Z","timestamp":1759838330459},"reference-count":30,"publisher":"Elsevier BV","issue":"36","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.vaccine.2017.06.053","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T23:45:15Z","timestamp":1498693515000},"page":"4745-4752","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial"],"prefix":"10.1016","volume":"35","author":[{"given":"Mari\u00ebtte B.","family":"van Ravenhorst","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona R.M.","family":"van der Klis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debbie M.","family":"van Rooijen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirjam J.","family":"Knol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne P.","family":"Stoof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth A.M.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy A.M.","family":"Berbers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2017.06.053_b0005","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.06.053_b0010","first-page":"759","article-title":"Regulation of capsule in Neisseria meningitidis","volume":"42","author":"Tzeng","year":"2016","journal-title":"Crit Rev Microbiol"},{"key":"10.1016\/j.vaccine.2017.06.053_b0015","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(02)08679-8","article-title":"Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination","volume":"359","author":"Maiden","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.06.053_b0020","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/cid\/ciu601","article-title":"A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination","volume":"59","author":"Bijlsma","year":"2014","journal-title":"Clin Infect Dis: Official Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2017.06.053_b0025","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/cid\/cis892","article-title":"Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity","volume":"56","author":"Kristiansen","year":"2013","journal-title":"Clin Infect Dis: Official Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2017.06.053_b0030","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/01.inf.0000195594.41449.c6","article-title":"Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands","volume":"25","author":"de Greeff","year":"2006","journal-title":"Pediatric Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.06.053_b0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2334-12-35","article-title":"Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands","volume":"12","author":"Kaaijk","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2017.06.053_b0040","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1473-3099(14)70806-0","article-title":"Epidemiology of invasive meningococcal disease in the Netherlands, 1960\u20132012: an analysis of national surveillance data","volume":"14","author":"Bijlsma","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.06.053_b0045","doi-asserted-by":"crossref","first-page":"6974","DOI":"10.1016\/j.vaccine.2009.09.082","article-title":"Kinetics of antibody responses after primary immunization with meningococcal serogroup C conjugate vaccine or secondary immunization with either conjugate or polysaccharide vaccine in adults","volume":"27","author":"de Voer","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.06.053_b0050","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1128\/CVI.00384-09","article-title":"Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine","volume":"17","author":"Borrow","year":"2010","journal-title":"Clin Vaccine Immunol: CVI"},{"key":"10.1016\/j.vaccine.2017.06.053_b0055","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/01.inf.0000151029.58752.27","article-title":"Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine","volume":"24","author":"Snape","year":"2005","journal-title":"Pediatric Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.06.053_b0060","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","article-title":"Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction","volume":"364","author":"Trotter","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.06.053_b0065","doi-asserted-by":"crossref","first-page":"e100651","DOI":"10.1371\/journal.pone.0100651","article-title":"Timing of an adolescent booster after single primary meningococcal serogroup C conjugate immunization at young age; an intervention study among Dutch teenagers","volume":"9","author":"Stoof","year":"2014","journal-title":"PloS one"},{"key":"10.1016\/j.vaccine.2017.06.053_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2016.10.049","article-title":"Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination","author":"van Ravenhorst","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.06.053_b0075","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CDLI.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin Diagnostic Lab Immunol"},{"key":"10.1016\/j.vaccine.2017.06.053_b0080","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/IAI.69.3.1568-1573.2001","article-title":"Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection","volume":"69","author":"Borrow","year":"2001","journal-title":"Infection Immunity."},{"key":"10.1016\/j.vaccine.2017.06.053_b0085","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2013serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.06.053_b0090","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/CDLI.10.5.780-786.2003","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagnostic Lab Immunol"},{"key":"10.1016\/j.vaccine.2017.06.053_b0095","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1128\/CVI.00478-07","article-title":"Development of a fluorescent-bead-based multiplex immunoassay to determine immunoglobulin G subclass responses to Neisseria meningitidis serogroup A and C polysaccharides","volume":"15","author":"de Voer","year":"2008","journal-title":"Clin Vaccine Immunol: CVI"},{"key":"10.1016\/j.vaccine.2017.06.053_b0100","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1128\/CVI.00364-08","article-title":"Simultaneous detection of Haemophilus influenzae type b polysaccharide-specific antibodies and Neisseria meningitidis serogroup A, C, Y, and W-135 polysaccharide-specific antibodies in a fluorescent-bead-based multiplex immunoassay","volume":"16","author":"de Voer","year":"2009","journal-title":"Clin Vaccine Immunol: CVI"},{"key":"10.1016\/j.vaccine.2017.06.053_b0105","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1128\/CDLI.11.2.272-279.2004","article-title":"Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135","volume":"11","author":"Lal","year":"2004","journal-title":"Clin Diagnostic Lab Immunol"},{"key":"10.1016\/j.vaccine.2017.06.053_b0110","doi-asserted-by":"crossref","first-page":"e0138665","DOI":"10.1371\/journal.pone.0138665","article-title":"Different dynamics for IgG and IgA Memory B cells in adolescents following a meningococcal serogroup C tetanus toxoid conjugate booster vaccination nine years after priming: a role for priming age?","volume":"10","author":"Stoof","year":"2015","journal-title":"PloS one"},{"key":"10.1016\/j.vaccine.2017.06.053_b0115","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.vaccine.2015.01.072","article-title":"Comparing vaccines: a systematic review of the use of the non-inferiority margin in vaccine trials","volume":"33","author":"Donken","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.06.053_b0120","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1016\/j.vaccine.2011.03.043","article-title":"Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial","volume":"29","author":"Vesikari","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.06.053_b0125","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1128\/IAI.69.4.2378-2382.2001","article-title":"Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains","volume":"69","author":"Richmond","year":"2001","journal-title":"Infection Immun"},{"key":"10.1016\/j.vaccine.2017.06.053_b0130","unstructured":"Ravenhorst MB, Bijlsma MW, van Houten MA, Struben VM, Anderson AS, Eiden J, et al. Meningococcal carriage in Dutch adolescents and young adults; A cross-sectional and longitudinal cohort study. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases; 2017."},{"key":"10.1016\/j.vaccine.2017.06.053_b0135","doi-asserted-by":"crossref","first-page":"e12144","DOI":"10.1371\/journal.pone.0012144","article-title":"Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine","volume":"5","author":"de Voer","year":"2010","journal-title":"PloS one"},{"key":"10.1016\/j.vaccine.2017.06.053_b0140","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1128\/CVI.13.4.507-510.2006","article-title":"Immunoglobulin G subclass response to a meningococcal quadrivalent polysaccharide-diphtheria toxoid conjugate vaccine","volume":"13","author":"Findlow","year":"2006","journal-title":"Clin Vaccine Immunol: CVI"},{"key":"10.1016\/j.vaccine.2017.06.053_b0145","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.4049\/jimmunol.180.4.2165","article-title":"The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response","volume":"180","author":"Blanchard Rohner","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.06.053_b0150","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.4161\/hv.20473","article-title":"Importance of circulating antibodies in protection against meningococcal disease","volume":"8","author":"Erlich","year":"2012","journal-title":"Human Vaccines Immunotherapeutics"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17308502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17308502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,11]],"date-time":"2020-10-11T03:57:45Z","timestamp":1602388665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17308502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":30,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0264410X17308502"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.06.053","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.06.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}